All In Biotech

Drug Trial Radar · NCT03207438

Melancholic Depression and Insomnia as Predictors of Response to Quetiapine in Patients With Major Depression

Last checked: Nov 20, 2026Latest source record: Dec 4, 2019 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingRandomized with 1,790 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

1,790

Actual

Start

Apr 2006

Primary completion

Jul 2007

Study completion Oct 2019

Sponsor

Lead sponsor
University of SaskatchewanAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
AstraZeneca
First posted
Jul 2, 2017

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Randomized
Model
Parallel
Masking
Double (participant, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 65 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

In essence the researchers are hoping to test two separate hypotheses (described below in the form of research questions). Therefore, the proposed analysis has been outlined according to each hypothesis. Hypothesis 1: Is low-dose quetiapine (50 mg/day) more effective for patients with depression who have insomnia at treatment baseline? (Stated differently: is low-dose quetiapine 50 mg/day effective as monotherapy for patients with depression regardless of whether or not they have insomnia at baseline?). Hypothesis 2: Is high-dose quetiapine (150 - 300 mg/day) more effective for patients presenting with melancholic depression at treatment baseline?

Conditions

  • Depressive Disorder, Major

Interventions

  • Quetiapine 50 MG Extended Release Oral TabletDrug

    OD

  • Quetiapine Fumarate XR 150-300 mgDrug

    Dose ranged from 150 to 300mg, XR preparation, OD

  • PlacebosDrug

    Placebo

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants With 50 Percent Or Greater Reduction in the MADRS Score Over Time for the Quetiapine XR 150-300mg and Placebo 2 Arms/Groups Stratified by Depression Type (Melancholic vs. Nonmelancholic)Time frame: 1 - 6 weeks
  2. Modified MADRS Response RatesTime frame: 1 - 6 weeks
  3. MADRS Response RatesTime frame: Day 4 - Week 6
  4. Modified MADRS Response RateTime frame: Day 4 - Week 6

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.